The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes
International Journal of Molecular Sciences · 05.04.2023 · 24 (7) · 6765
DOI: 10.3390/ijms24076765 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.04.2023. Verfasst von Simon Blaine-Sauer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology and Communication Science, Medical College of Wisconsin, Milwaukee, WI 53226, USA. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Laryngopharyngeal Reflux. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical College of Wisconsin Department of Otolaryngology and Communication Sciences, Dr. Jamie Koufman, Mr. Eric Becker and his family.
Abstract (Originalsprache)
Gastroesophageal reflux disease (GERD) significantly impacts patient quality of life and is a major risk factor for the development of Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC). Proton pump inhibitors (PPIs) are the standard-of-care for GERD and are among the most prescribed drugs in the world, but do not protect against nonacid components of reflux such as pepsin, or prevent reflux-associated carcinogenesis. We recently identified an HIV protease inhibitor amprenavir that inhibits pepsin and demonstrated the antireflux therapeutic potential of its prodrug fosamprenavir in a mouse model of laryngopharyngeal reflux. In this study, we assessed the capacity of amprenavir to protect against esophageal epithelial barrier disruption in vitro and related molecular events, E-cadherin cleavage, and matrix metalloproteinase induction, which are associated with GERD severity and esophageal cancer. Herein, weakly acidified pepsin (though not acid alone) caused cell dissociation accompanied by regulated intramembrane proteolysis of E-cadherin. Soluble E-cadherin responsive matrix metalloproteinases (MMPs) were transcriptionally upregulated 24 h post-treatment. Amprenavir, at serum concentrations achievable given the manufacturer-recommended dose of fosamprenavir, protected against pepsin-induced cell dissociation, E-cadherin cleavage, and MMP induction. These results support a potential therapeutic role for amprenavir in GERD recalcitrant to PPI therapy and for preventing GERD-associated neoplastic changes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology and Communication Science, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
- Department of Pediatrics Quantitative Health Sciences, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
- Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
ORCID-Profile: Simon Blaine-Sauer, Tina L Samuels
Förderung
- Medical College of Wisconsin Department of Otolaryngology and Communication Sciences
- Dr. Jamie Koufman
- Mr. Eric Becker and his family
Zitieren
APA
Blaine-Sauer, S., Samuels, T. L., Yan, K., & Johnston, N. (2023). The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes. International Journal of Molecular Sciences, 24(7), 6765. https://doi.org/10.3390/ijms24076765
Vancouver
Blaine-Sauer S, Samuels TL, Yan K, Johnston N. The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes. International Journal of Molecular Sciences. 2023;24(7):6765. doi:10.3390/ijms24076765
BibTeX
@article{BlaineSauer2023,
author = {Blaine-Sauer, Simon and Samuels, Tina L and Yan, Ke and Johnston, Nikki},
title = {The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {7},
pages = {6765},
doi = {10.3390/ijms24076765}
}
EUVIMED